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S U M M A R Y
Background: Recent data suggest that varicella zoster virus (VZV)-associated complications of the central
nervous system (CNS) are more common and diverse than previously thought. The main purpose of this
article is to describe the clinical characteristics and the outcome of patients suffering from meningitis
and encephalitis caused by VZV reactivation.
Methods: A retrospective case study of adult patients (16 years old) diagnosed with a VZV reactivation
in the CNS was performed. The cases were identiﬁed by a qualitative PCR DNA assay of the cerebrospinal
ﬂuid (CSF) at the Regional Hospital of Lugano between January 1, 2003 and July 31, 2010.
Results: Eleven out of 519 CSF samples (2.1%), submitted from patients with a clinical diagnosis of viral
meningitis or encephalitis, were positive for VZV. A vesiculo-pustular skin eruption was observed in only
ﬁve patients (45%). In six cases (55%), a systemic inﬂammatory syndrome was absent. The clinical
outcome was favorable in eight patients (73%). Only one out of 11 patients (9%) died. The four patients
with encephalitis had a less favorable prognosis: one patient recovered without residual neurological
sequelae; two had a chronic neuropsychological handicap, speech difﬁculties, facial nerve palsy, and
focal seizures; one patient died. We estimated an annual incidence rate of VZV infection of the CNS of
1.02/100 000 inhabitants for southern Switzerland.
Conclusions: Screening of CSF for VZV by PCR is recommended for all patients with encephalitis and for
those with viral meningitis of unclear origin in order to better target antiviral treatment.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Varicella zoster virus (VZV) is ubiquitous throughout the world.
Initial infection with VZV results in chickenpox (varicella), which is
typically seen in children aged 1–9 years. In most temperate
climates, more than 90% of people are infected before adolescence.1
Recent data suggest that central nervous system (CNS) complications
caused by VZV reactivation are more common than previously
thought.2 VZV is the third most frequent causal agent of viral
meningitis after enterovirus and herpes simplex virus type 2, with
a frequency ranging from 5% to 29%.3–5 Since the introduction
of DNA ampliﬁcation by PCR for the diagnosis of VZV in the CNS
at the beginning of the 1990s, the number of diagnosed cases
has increased.6 However, only a few epidemiological studies* Corresponding author. Tel.: +41 91 8116022; fax: +41 94 8116031.
E-mail address: Enos.Bernasconi@eoc.ch (E. Bernasconi).
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http://dx.doi.org/10.1016/j.ijid.2013.01.031are available in which clinical characteristics and outcome are
described.
Infectious manifestations referring to the CNS are multiple and
include myelopathy, encephalitis, meningitis, and vasculopathy.2
The possibility of infectious reactivation without the characteristic
vesicular rash (zoster sine herpete) makes the diagnosis even more
difﬁcult.
The main purpose of this article is to describe the clinical
characteristics and the outcome of patients suffering from
meningitis and encephalitis caused by VZV reactivation seen at
a community-based hospital.
2. Methods
2.1. Study design
This was a retrospective study based on the review of the
clinical characteristics of adults (16 year old) suffering a VZVses. Published by Elsevier Ltd. All rights reserved.
Table 1
Annual distribution of cases of CNS infections caused by VZV, 2003–2010
Year Total number of
positive samples
Positive sample
results
2003 42 (8.1%) 2 (18%)
2004 40 (7.7%) 2 (18%)
2005 71 (13.6%) 3 (27%)
2006 75 (14.4%) 0
2007 80 (15.4%) 1 (9%)
2008 75 (14.4%) 0
2009 93 (17.9%) 1 (9%)
Until May 2010 43 (8.2%) 2 (18%)
Total 519 (100%) 11 (100%)
CNS, central nervous system; VZV, varicella zoster virus.
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ﬂuid (CSF).
2.2. Data collection
We collected clinical information on patients with infection of
the CNS caused by VZV admitted to the emergency department of
the Regional Hospital of Lugano between January 1, 2003 and July
31, 2010. The decision to perform a PCR test for VZV was taken by
the emergency physician. Patients with neurological symptoms,
detectable VZV DNA in the CSF, and available clinical records were
included in the study.
The Regional Hospital of Lugano is a 280-bed facility and the
main referral hospital for about 134 000 inhabitants.6 Lugano is the
largest city of the Canton of Ticino, a region of southern
Switzerland with a population of 340 000.7 PCR for the detection
of VZV DNA was developed in the early nineties, but its use has
become widespread in the last 10 years. Virological diagnosis is
performed at the Bellinzona’s Cantonal Institute of Microbiology, a
laboratory that has offered VZV PCR in the CSF since 2001 and
processes all samples of suspected cases in Ticino. This enabled us
to estimate the average annual incidence of infections of the CNS
caused by VZV for our region.
2.3. Case deﬁnition
Viral meningitis was deﬁned as: symptoms and/or signs of
meningeal inﬂammation without evidence of brain parenchymal
involvement; CSF leukocyte count over 5  106/l; a negative CSF
bacterial culture; and the absence of a non-infectious etiology to
explain the clinical ﬁndings. Encephalitis was diagnosed if the
patient presented signs of cerebral parenchymal involvement, i.e.
acutely altered consciousness or personality changes, epileptic
seizures or focal neurologic signs, and either an elevated CSF white
blood cell count (WBC) (over 5  106/l) or protein level >40 mg/l,
or neuroradiological and electroencephalogram (EEG) ﬁndings
consistent with encephalitis.
In the absence of an immunocompromising disease or
immunosuppressive drugs, the patients were considered to be
immunocompetent.
Descriptive statistics were performed by means of Excel
software (Microsoft Corp.).
2.4. VZV nucleic acid extraction, PCR, and melting curve analysis
Nucleic acids were extracted from a 0.2-ml volume of CSF by
total nucleic acid protocol on a MagNA Pure Compact instrument
(Roche Molecular Biochemical) in accordance with the manufac-
turer’s instructions. DNA was eluted in a ﬁnal volume of 100 ml. All
samples were ampliﬁed by LightCycler PCR (Roche) with primers
directed to ORF 29 of the virus: sense, 50-TGT CCT AGA GGA GGT
TTT ATC TG-30; antisense primer, 50-CAT CGT CTG TAA GAC TTA
ACC AG-30, as previously described.8 The composition of the master
mix was as previously described,8 except for the use of FastStart
DNA Master SYBR Green and the addition of dUTP/uracil
glycosylase for the prevention of carry-over contaminations.
For the assay, a 5-ml aliquot of nucleic acid extract was added to
15 ml of PCR mixture in each reaction capillary. All capillaries were
then sealed and ampliﬁed using the following protocol: 37 8C for
10 min for one cycle, 95 8C for 10 min for one cycle to activate
HotStart Taq polymerase, followed by denaturation at 95 8C for 10
s, 10 s of annealing at 62 8C, and 12 s of primer extension at 72 8C
for 45 cycles.
To demonstrate the speciﬁcity of the PCR product, a melting
curve analysis was performed following PCR ampliﬁcation.
Starting at 54 8C, the temperature in the thermal chamber wasslowly raised (0.2 8C/s) to 95 8C, and ﬂuorescence measured
continuously. PCR products of the expected ampliﬁed fragment
of gene 29 produce a melting curve peaking at 66–68 8C.
3. Results
During the study period, 11 cases were diagnosed out of 519 CSF
samples tested for VZV (2.1%). We observed a progressive increase
in the requests for a VZV test for CNS infections following the
introduction of the speciﬁc DNA PCR technique at our microbiology
laboratory. Despite this increased diagnostic activity, the incidence
of identiﬁed cases remained unchanged. The average annual
incidence of CNS infections caused by VZV during the period 2003–
2010 stands at 1.02 (standard deviation 0.79) cases for 100 000
inhabitants.
The median age of patients with VZV reactivation in the CNS
was 48 years (range 27–75 years), with only three patients over the
age of 60 years. Seven patients (64%) were men (Table 1). The most
frequent symptoms and signs were headache (64%), fever (54%),
and neck stiffness (27%). In six patients (55%), a systemic
inﬂammatory syndrome (WBC >10  106/l and C-reactive protein
(CRP) >5 mg/l) was absent. A vesiculo-pustular skin eruption was
observed in ﬁve patients (45%) (Tables 1 and 2). Only two patients
(18%) were immunodeﬁcient. One patient had an advanced HIV
disease (Centers for Disease Control and Prevention (CDC) stage C),
the second was receiving immunosuppressive therapy with
azathioprine and cyclosporine after renal transplantation. The
median length of hospital stay was 14 days (range 2–43 days). Ten
patients (91%) received the recommended treatment with
intravenous acyclovir (10–15 mg/kg body weight every 8 h for
10 days). The course was favorable in eight cases (73%). Only the
patient with advanced HIV disease died; death occurred on the
second day after admission. He displayed behavioral changes with
no rise in CSF WBC and therefore he did not receive a speciﬁc
antiviral treatment.
Seven patients (64%) fulﬁlled the criteria for aseptic meningitis
(Table 1). The median age of these patients was 48 years (range 27–
68 years), ﬁve (71%) were males. All had headache, ﬁve (71%) had
fever, and two (29%) had neck stiffness. The characteristic rash was
absent in three (43%) of the cases. In three patients (43%), the
systemic inﬂammatory parameters were normal. The median CSF
WBC was 398  106/l (range 82–1167  106/l) and the protein
concentration was 1101 mg/l (range 600–2180 mg/l). Six patients
underwent neuroimaging: three magnetic resonance imaging
(MRI) and three computed tomography (CT) scan. All the
radiological ﬁndings were reported as normal or showing
abnormalities consistent with pre-existing lesions. The median
length of hospital stay was 11 days (range 5–21 days). The outcome
was favorable in 100% of the meningitis cases.
Four patients (36%) fulﬁlled the criteria for encephalitis
(Table 1). The median age of these patients was 57 years (range
Table 2
Clinical manifestations, laboratory results, and therapy of the patients suffering from VZV reactivation in the CNS, 2003–2010
Diagnosis Year Sex Age Clinical manifestations Rash HIV
status
Other
immunosuppressive
conditions
WBC, 
109/l
PCR,
mg/l
Leukocytes
in CSF, 106/l
Protein in
CSF, mg/l
Duration of
hospital
stay, days
Outcome Therapy
Meningitis 2003 M 59 Headache, fever Present Neg No 7 1.9 360 1270 11 No neurological
sequelae
Acyclovir IV
Meningitis 2004 M 49 Headache, fever Present Neg No 10.8 3 82 600 5 No neurological
sequelae
Acyclovir IV
Meningitis 2005 M 36 Headache Absent Neg No 11.1 2 1157 2180 6 No neurological
sequelae
Acyclovir IV
Meningitis 2005 F 48 Headache, fever Present Neg No 8.3 0 237 740 14 No neurological
sequelae
Acyclovir IV
Meningitis 2005 M 28 Headache,
fever, neck stiffness
Absent Neg No 10 0.5 120 730 21 No neurological
sequelae
Acyclovir IV
Meningitis 2009 M 27 Headache, photophobia
neck stiffness
Absent Neg No 10 0.5 403 1292 15 No neurological
sequelae
Acyclovir IV and
valacyclovir PO
Meningitis 2010 F 68 Headache fever Present Neg No 8.7 4 426 894 11 No neurological
sequelae
Acyclovir IV
Encephalitis 2004 F 48 Fever, drowsiness,
dysarthria
Absent ND No 14.1 35.8 2 280 14 Neuropsychological
sequelae
Acyclovir IV
Encephalitis 2006 M 36 Altered consciousness Absent Pos No 2.7 124.3 2 280 2 Died No
Encephalitis 2007 M 66 Ocular pain, focal
seizures at EEG
Present
(herpes
ophthalmicus)
Neg Immunosuppressive
therapy with
azathioprine and
cyclosporine
21 6.6 17 475 43 Focal seizures Acyclovir IV
Encephalitis 2010 F 75 Headache, VII cranial
nerve palsy
Herpes oticus Neg No 12.9 4 167 735 24 No neurological
sequelae
Acyclovir IV and
valacyclovir PO
CNS, central nervous system; CSF, cerebrospinal ﬂuid; EEG, electroencephalogram; F, female; IV, intravenous; M, male; ND, not determined; PCR, polymerase chain reaction; PO, per os (oral); VZV, varicella zoster virus; WBC, white
blood cell count.
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Table 3
Clinical features and outcome of patients with CNS infection caused by VZV reactivation in the medical literature, 2000–2011
Year Country Design
of study
Number of
patients
Women Immunocompromised
patients
Presence of rash
in VZV cases
Patients with
VZV encephalitis
Patients with
VZV meningitis
Other clinical
presentations
Outcome of patients
with VZV encephalitis
Outcome of
patients with
VZV meningitis
Mortality Ref.
2012 Israel Retrospective 20 12 (60%) 0 100% 12 (60%) 8 (40%) 0 2 (10%) mild
neurological
sequelae
Favorable 0 12
2011 USA Prospective 26 50% 10 (38.4%) 11 (42%) 13 (50%) 10 (38.4%) 3 (11.5%) ADEM NAV NAV NAV 11
2009 Sweden Retrospective 97 NAV 12 (12.3%) 62 (63.9%) 34 (35%) 28 (28.9%) 39 (40.2%)
encephalopathy,
cerebrovascular
disease
10 (29.4%) severe
neurological
sequelae
7 (25%) mild
neurological
sequelae
2 (2%) 10
2009 Australia Retrospective 5926 NAV NAV NAV 226 (3.8%) NAP NAP NAV NAP NAP 21
2009 France Prospective 253 39% NAV NAV 20 (7.9%) NAP 0 NAV NAP 3 (1.1%) 22
2008 UK Retrospective 59 NAV 24 (40.6%) 7 (70%) NAP 10 (16.9%) NAP NAP NAV NAV 13
2008 Greece Prospective 81 NAV NAV NAV 0 2 (2.4%) 0 NAP Favorable 0 3
2006 Finland Prospective 144 52.7% 0 9 (75%) NAP 12 (8.3%) NAP NAV NAV NAV 5
2005 Austria Retrospective 30 40% 4 (13.3%) 8 (26.6%) 13 (43.3%) 17 (56.6%) NAP NAV NAP 1 (3.3%) 24
2003 Taiwan Prospective 41 42.5% NAV NAV 5 (12.1%) NAP NAP NAV NAP NAV 23
2003 Germany Retrospective 43 NAV NAV 1 (50%) NAP 2 (4.6%) NAP NAP 1 (2.5%) mild
to moderate
headache
or cognitive
deﬁcits
0 18
2001 UK Retrospective 15 26.6% 15 (100%) 4(44.4%) 9 (60%) NAP 6 (40%) isolated
cranial nerve
palsies
1 (6.6%) severe
neurological
sequelae
NAP 2 (13.3%) 15
2000 France Prospective 34 NAP 34 (100%) 24 (70.5%) 13 (38.2%) 6 (18%) 15 (44%)
radiculitis, myelitis
4 (33%) severe
neurological
sequelae
NAV 6 (17.6%) 14
ADEM, acute disseminated encephalomyelitis; CNS, central nervous system; NAP, not applicable; NAV, not available; VZV, varicella zoster virus.
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of encephalitis were multiple: three displayed focal symptoms
including speech difﬁculties, central facial palsy, and focal seizures.
One patient had headache and another had fever. The median
length of hospital stay in the encephalitis group was 19 days (range
2–43 days). Only two cases had the characteristic rash, whereas a
systemic inﬂammatory syndrome was present in all cases. The
median WBC in CSF was 47  106/l (range 2–167  106/l) and the
protein concentration was 442 mg/l (range 280–735 mg/l). In two
patients the leukocyte count in the CSF was normal. All patients
had neuroimaging studies. Two had an MRI and two a CT scan. All
the radiological images were found to be normal or showing
abnormalities consistent with pre-existing lesions. One of the
patients had an advanced HIV infection (CDC stage C3). The median
length of hospital stay was 19 days (range 2–43 days). The
diagnosis of encephalitis was associated with a worse outcome.
Only one patient recovered without neurological sequelae. Two
patients demonstrated important neuropsychological deﬁciencies
and one patient died.
4. Discussion
Varicella zoster reactivation in the CNS is associated with a
variety of serious and potentially lethal complications in both
immunocompetent and immunocompromised individuals. In
contrast to the classic textbook descriptions,10 the present case
series is characterized by the predominance of immunocompetent
patients aged <60 years. Our results are therefore comparable to
those reported by Persson et al. in Sweden,10 Pahud et al. in
California,11 and Pollak et al. in Israel,12 where the percentages of
patients with immunodeﬁciency were 38%, 12%, and 10%,
respectively.
Another important difference between our study and earlier
publications is the frequent absence of skin lesions, which were
reported in only 45% of cases, as well as a missing systemic
inﬂammatory syndrome in 55% of cases in the present study. In this
respect, our results are comparable to those observed in the studies
carried out by Persson et al.10 and Pahud et al.,11 in populations
with similar percentages of patients with an immunodeﬁciency.
Traditionally, the vesicular rash is regarded as a characteristic
ﬁnding for viral reactivation. However, several recent studies have
conﬁrmed the low sensitivity of this clinical sign, which is absent in
more than a third of cases of CNS infection (Table 3).
The systemic inﬂammatory parameters were normal in almost
half of our cases with meningitis. This observation was even more
striking in the study by Ihekwaba et al.,13 where the mean level of
CRP and the mean leukocyte count were within the normal range
in patients with VZV meningitis. In the case series of Pollak et al.,
the mean leukocyte count was within the normal range in 85% of
patients with a diagnosis of CNS VZV infection.12
CSF pleocytosis was absent in half of our small group of patients
with encephalitis. This phenomenon is mainly observed in HIV-
infected patients with VZV encephalitis (33–40%).14,15 Neverthe-
less, Persson found 5% of patients without CSF pleocytosis9 in a
mixed population of immunocompetent and immunocompro-
mised individuals. In fact, inﬂammatory parameters were higher in
meningitis compared to encephalitis cases in the present study.
This suggests that the inﬂammatory response may be related to
immune mechanisms protecting from parenchymal involvement.
In our series, all the brain images (MRI or CT scan) were deemed
normal or to be showing pre-existing abnormalities. Normal
neuroimaging was also a common ﬁnding in the Pollak case
series.12 Radiological imaging provides an inconstant contribution
to the diagnosis of VZV encephalitis. Brain CT scans are generally
unremarkable and are potentially useful to exclude alternative
diagnoses such as hemorrhage or tumor. In contrast, severalspeciﬁc MRI abnormalities have been described in VZV encephali-
tis. In the case series integrating neuroimaging descriptions, the
percentage of abnormal neuroimaging ranged from 20% to
70%.11,14,15 Brain MRI usually reveals areas of high signal intensity
on T2-weighted sequence at the gray–white matter junction and in
the deep white matter, or abnormal enhancement.14,154
Seventy-ﬁve percent of our patients were treated with
intravenous acyclovir, as recommended by the Infectious Diseases
Society of America for patients with VZV encephalitis.16 This
recommendation is, however, based on small case studies. No
clinical trial with a signiﬁcant number of patients has ever
established the efﬁcacy of antiviral therapy for VZV meningitis and
encephalitis. Although only occasional reports have shown a
clearance of VZV DNA from the CNS with antiviral treatment,16
intravenous acyclovir is considered the standard treatment,
because of the documented efﬁcacy in other VZV manifestations,
the low potential for drug-related adverse events, and the
signiﬁcant morbidity associated with VZV CNS complications.15,16
Guidelines for the treatment of VZV meningitis are not available.
Nevertheless, the use of acyclovir 5–10 mg/kg intravenous (IV)
every 8 h for 10–14 days is common practice.13 The totality of our
cases with meningitis was treated with a similar regimen.
All our meningitis cases recovered without neurologic sequelae.
The outcome of meningitis cases is highly variable. In the few
studies available, the outcome has differed from favorable to
poor.17,18 Persson et al. reported neurological sequelae in 50% of
their patients with VZV meningitis at 1 month of follow up.9 In
contrast, VZV encephalitis is generally considered a severe disease
with a poor prognosis, as observed in our series. The mortality of
varicella encephalitis ranges from 5% to 15% (Table 3). Long-term
sequelae, including seizure disorders and neuropsychological
sequelae, are reported in 10–50% of survivors. Among cases of
encephalitis in HIV patients, mortality has been high (33%) and
sequelae frequent (33%), despite antiviral therapy14,15 (Table 3).
In studies reporting on follow-up, neurological complications
appear to be more frequent in patients who did not develop a
characteristic rash.9 The absence of the typical skin manifestation
may delay the recognition of VZV CNS infection and hence the
initiation of a speciﬁc antiviral therapy, thus negatively affecting
the outcome.3,9,19,20 Antiviral treatment might also be prematurely
discontinued once the routinely tested herpes simplex virus (HSV)
is ruled out.
As pointed out by Pollak and co-workers,12 differentiation
between VZV and HSV CNS infections in the absence of a
dermatological rash represents a true challenge. In their study,
patients with VZV CNS infections did not differ from patients with
HSV CNS infections, neither in demographic characteristics, nor in
clinical presentation. These ﬁndings highlight the importance of
testing CSF for both HSV and VZV if meningitis of viral origin is
suspected.
Until the mid 1990s, infectious complications of the CNS caused
by VZV reactivation were regarded as an atypical appearance of low
frequency.3,19 The presence of the distinctive skin rash, as well as
speciﬁc neurological symptoms, were required to diagnose a CNS
infection caused by VZV.3,19The introduction of the PCR technique to
detect VZV in the CSF was followed by a signiﬁcant increase in the
number of diagnosed cases.6 PCR testing has been instrumental in
the identiﬁcation of VZV as the cause of CNS infections, particularly
in the absence of skin manifestations.6 Several studies performed in
the last decade in countries such as Austria,24 Australia,21 Finland,4
France,22 Germany,18 Greece,3 Israel,12 Taiwan,23 and the UK13 have
led to the conclusion that VZV is the third most frequent viral agent
causing CNS disease in adults. In these studies, samples of suspected
cases were tested for the most frequent viral agents. The structure of
these studies made it possible to diagnose a large number of cases
where the characteristic rash was absent. However, these studies
J.C.L. Becerra et al. / International Journal of Infectious Diseases 17 (2013) e529–e534e534conducted by reference laboratories provided little information on
clinical presentation and outcomes of VZV reactivation in the CNS
(Table 3).
Our data show that CNS infections caused by VZV can be
observed, in a not negligible frequency, at the emergency
department of a community hospital. For our region we estimated
an incidence rate of 1.02 cases per 100 000 inhabitants. Given the
multiple clinical and laboratory criteria used by different study
groups and the limited data available, a comparison with other
reports is very difﬁcult. In Sweden, the annual incidence of VZV
CNS infections is reported to be 1.8 cases per 100 000 inhabitants.9
Our study is limited by the retrospective design, which may
have precluded the inclusion of all CNS infections caused by VZV
diagnosed during the period considered for this study. We cannot
exclude that patients presenting to the emergency department
with meningitis or encephalitis and a typical rash were not more
frequently tested for VZV in the CSF than patients without skin
manifestations. Nevertheless, the possibility of including informa-
tion on clinical presentation, laboratory results, and outcomes of
patients with VZV reactivation in the CNS represents a clear
strength of our study in comparison to previous reports.
In conclusion, VZV reactivation in the CNS remains a challenge
for the emergency physician. The clinical manifestations of VZV
CNS complications are variable, non-speciﬁc, and indistinguishable
from those of other viral CNS infections. Screening for VZV by PCR
in the CSF is recommended for all patients with encephalitis and
for those with viral meningitis of unknown origin in order to better
target antiviral treatment.
Conﬂict of interest: No conﬂict of interest to declare.
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